Hester Biosciences Limited has made the audio recording of its earnings conference call for the first quarter of FY27 (Q1FY27) available to investors on its official website. The disclosure, filed with BSE Limited and the National Stock Exchange of India Limited on July 30, 2026, confirms that the teleconference discussing financial results for the quarter ended June 30, 2026, has concluded and is now accessible for public review.

The filing cites compliance with Regulations 30 and 46(2)(oa) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Vinod Mali, Company Secretary & Compliance Officer, signed the notice, which provides a direct link to the audio recording hosted at www.hester.in . This step ensures transparency and allows shareholders who could not attend the live session on July 30 to access management’s commentary on the company’s performance.

Earnings Call Details

The conference call was originally scheduled for Thursday, July 30, 2026, at 2:00 p.m. IST. It was coordinated by ICICI Securities, which facilitated investor participation through a Diamond Pass registration link. The session featured senior management executives addressing queries regarding operational performance and financial outcomes for Q1FY27.

Accessing the Recording

Investors can listen to the complete audio recording via the link provided in the exchange filing: https://www.hester.in/information/earnings-call . The recording covers discussions on revenue trends, profit margins, and strategic initiatives undertaken during the quarter. For logistical clarifications regarding the event, contact details were previously provided for Jaideep Goswami, Head of Equities, along with other designated coordinators including Abdulkader Puranwala, Rushad Kapadia, Seema Sehgal, and Minali Ginwala.

What This Means for Investors

The availability of the audio recording allows market participants to analyze management’s tone and specific responses to investor questions without waiting for a separate transcript. While the filing itself does not disclose new financial metrics such as net profit or revenue figures, it confirms that the internal reporting process for Q1FY27 is complete. Investors should review the recording to gain insights into future guidance and operational challenges discussed during the live interaction.

Hester Biosciences Limited has completed the reclassification of two key stakeholders from the Promoter Group to the Public category, a move that alters the company’s shareholding structure without changing total promoter holding percentages in aggregate but shifts individual classification status. The National Stock Exchange of India Limited (NSE) and BSE Limited granted their respective no-objection approvals on July 24, 2026, validating the application submitted by the company on May 19, 2026. This regulatory clearance allows the shares held by Ravin Gandhi and Bela Gandhi to be treated as part of the public float for listing compliance purposes, potentially impacting liquidity metrics and shareholder composition disclosures.

The reclassification was executed under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs the transfer of shares between different categories of shareholders. Hester Biosciences Limited filed an intimation with both exchanges on July 25, 2026, referencing earlier submissions made on May 15, 2026, and May 20, 2026, which laid the groundwork for the final approval. Vinod Mali, Company Secretary and Compliance Officer at Hester Biosciences, signed the disclosure letter, confirming that the necessary procedural steps had been completed and that the exchange approvals were enclosed with the filing.

Regulatory Approvals Details

Both stock exchanges issued formal no-objection letters on the same day, ensuring synchronized compliance across trading platforms. The NSE approval was documented under reference number NSE/LIST/COMP/HESTERBIO/594/2026-2027, while BSE issued its approval under reference number LIST/COMP/SJ/150/2026-27. These documents explicitly list the individuals subject to reclassification and mandate continued adherence to material event disclosures related to this change.

The approval letters were signed by senior listing compliance officials from both exchanges. At BSE, Jayshree Soni, Deputy Vice President, and Sayli Jadhav, Deputy Manager, Listing Compliance, authorized the decision. At NSE, Apeksha Raichura, Senior Manager – Listing Compliance, provided the corresponding authorization. Both exchanges copied the National Securities Depository Limited (NSDL) and Central Depository Services Limited (CDSL) in their communications, ensuring depository records align with the new shareholding classifications.

What This Means for Shareholding Structure

Reclassification from the Promoter Group to the Public category is a significant structural adjustment for listed entities in India. While it does not necessarily imply a sale of shares or a change in beneficial ownership control, it does affect how the shares are categorized for regulatory reporting, particularly regarding public float requirements and insider trading regulations. For Hester Biosciences, this change means that the holdings of Ravin Gandhi and Bela Gandhi will no longer be aggregated under the 'Promoter and Promoter Group' column in standard shareholding pattern filings but will instead appear under the 'Public' category.

This shift can have implications for market perception and technical compliance. A higher public float percentage can sometimes enhance liquidity and broaden the investor base, as more shares are available for trading by retail and institutional investors who are not classified as promoters. However, it also means that any future transactions by these individuals will be subject to different disclosure norms compared to those applicable to promoter group members. The company must now ensure that all subsequent material events related to these shareholders are disclosed in accordance with Regulation 31A, maintaining transparency with the investing public.

The process began with the company’s application on May 19, 2026, followed by preliminary submissions in mid-May. The swift approval within six weeks suggests that the regulatory bodies found the documentation complete and compliant with existing norms. As Hester Biosciences moves forward, investors should monitor future shareholding pattern filings to observe the practical impact of this reclassification on the company’s capital structure and trading dynamics.